Inflammatory bowel disease: Epidemiology, pathology and risk factors for hypercoagulability

World Journal of Gastroenterology

Volumn 20, Issue 1, 2014, Pages 53-63

  Owczarek, Danuta ^a   Cibor, Dorota ^a   Głowacki, Mikołaj K ^a   Rodacki, Tomasz ^a   Mach, Tomasz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Crohn's disease; Hypercoagulation; Risk factors; Thrombosis; Ulcerative colitis

Indexed keywords

ALPHA INTERFERON; ANTICOAGULANT AGENT; ANTITHROMBIN III; AUTOANTIBODY; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; GLUCOCORTICOID; HEPARIN; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; LOW MOLECULAR WEIGHT HEPARIN; MERCAPTOPURINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1;

ANTICOAGULATION; ARTICLE; AUTOPSY; BLOOD CLOTTING; DISEASE EXACERBATION; DRUG MEGADOSE; ENDOTHELIUM LESION; FIBRINOLYSIS; GENE MUTATION; GENETIC ASSOCIATION; HEREDITY; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; IMMUNE DEFICIENCY; INFLAMMATORY BOWEL DISEASE; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; THROMBOCYTE AGGREGATION; THROMBOSIS; ULCERATIVE COLITIS; VENOUS THROMBOEMBOLISM;

CROHN'S DISEASE; HYPERCOAGULATION; RISK FACTORS; THROMBOSIS; ULCERATIVE COLITIS;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 84891788136     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i1.53     Document Type: Article

References (78)

1. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, Grisar J, Machold K, Scholz S, Vogelsang H, Novacek G. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53: 542-548 [PMID: 15016749 DOI: 10.1136/gut.2003.025411]
2. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85: 430-434 [PMID: 11307809]
3. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011; 106: 713-718 [PMID: 21407182 DOI: 10.1038/ajg.2011.53]
4. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut 1993; 34: 247-251 [PMID: 8432482 DOI: 10.1136/gut.34.2.247]
5. Talbot RW, Heppell J, Dozois RR, Beart RW. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61: 140-145 [PMID: 3080643 DOI: 10.1016/ S0025-6196(12)65200-8]
6. Sloan WP, Bargen JA, Gage RB. Life histories of patients with chronic ulcerative colitis: a review of 2,000 cases. Gas troenterology 1968; 54(Suppl): 822 [PMID: 5659826]
7. Scaldaferri F, Lancellotti S, Pizzoferrato M, De Cristofaro R. Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. World J Gastroenterol 2011; 17: 594-608 [PMID: 21350708 DOI: 10.3748/wjg.v17.i5.594]
8. Bernhard H, Deutschmann A, Leschnik B, Schweintzger S, Novak M, Hauer A, Muntean W. Thrombin generation in pediatric patients with Crohn's disease. Inflamm Bowel Dis 2011; 17: 2333-2339 [PMID: 21287673 DOI: 10.1002/ ibd.21631]
9. Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000; 35: 619-623 [PMID: 10912662 DOI: 10.1080 /003655200750023589]
10. Spina L, Saibeni S, Battaglioli T, Peyvandi F, de Franchis R, Vecchi M. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol 2005; 100: 2036-2041 [PMID: 16128949 DOI: 10.1111/ j.1572-0241.2005.42029.x]
11. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99: 97-101 [PMID: 14687149 DOI: 10.1046/j.1572-0241.2003.04026.x]
12. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 2272-2280 [PMID: 18684186 DOI: 10.1111/ j.1572-0241.2008.02052.x]
13. Novacek G, Weltermann A, Sobala A, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Miehsler W, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Eichinger S. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139: 779-87, 787.e1 [PMID: 20546736]
14. Okoro NI, Kane SV. Gender-related issues in the female inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol 2009; 3: 145-154 [PMID: 19351285 DOI: 10.1586/ egh.09.1]
15. Suárez Ferrer C, Vera Mendoza MI, Amo San Román L, González Lama Y, Calvo Moya M, García Casas M, Abreu García L. Risk of thromboembolic phenomena in patients with inflammatory bowel disease. Gastroenterol Hepatol 2012; 35: 634-639 [PMID: 23036695 DOI: 10.1016/j.gasrohp.2012.07.003]
16. Kappelman MD, Horvath-Puho E, Sandler RS, Rubin DT, Ullman TA, Pedersen L, Baron JA, Sørensen HT. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60: 937-943 [PMID: 21339206 DOI: 10.1136/ gut.2010.228585]
17. Barclay AR, Keightley JM, Horrocks I, Garrick V, McGrogan P, Russell RK. Cerebral thromboembolic events in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 677-683 [PMID: 19824070 DOI: 10.1002/ ibd.21113]
18. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 657-663 [PMID: 20149425 DOI: 10.1016/S0140-6736(09)61963-2]
19. van Bodegraven AA, Schoorl M, Linskens RK, Bartels PC, Tuynman HA. Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis. Eur J Gastroenterol Hepatol 2002; 14: 413-418 [PMID: 11943956 DOI: 10.1097/00042737-200204000-00014]
20. Tsiolakidou G, Koutroubakis IE. Thrombosis and inflammatory bowel disease-the role of genetic risk factors. World J Gastroenterol 2008; 14: 4440-4444 [PMID: 18680221 DOI: 10.3748/wjg.14.4440]
21. Twig G, Zandman-Goddard G, Szyper-Kravitz M, Shoenfeld Y. Systemic thromboembolism in inflammatory bowel disease: mechanisms and clinical applications. Ann N Y Acad Sci 2005; 1051: 166-173 [PMID: 16126956 DOI: 10.1196/ annals.1361.058]
22. Dacha S, Devidi M, Osmundson E. Budd-Chiari syndrome in a patient with ulcerative colitis and no inherited coagulopathy. World J Hepatol 2011; 3: 164-169 [PMID: 21860676 DOI: 10.4254/wjh.v3.i6.164]
23. Di Fabio F, Obrand D, Satin R, Gordon PH. Intra-abdominal venous and arterial thromboembolism in inflammatory bowel disease. Dis Colon Rectum 2009; 52: 336-342 [PMID: 19279432 DOI: 10.1007/DCR.0b013e31819a235d]
24. Novotny DA, Rubin RJ, Slezak FA, Porter JA. Arterial thromboembolic complications of inflammatory bowel disease. Report of three cases. Dis Colon Rectum 1992; 35: 193-196 [PMID: 1735324 DOI: 10.1007/BF02050678]
25. Levy PJ, Tabares AH, Olin JW. Lower extremity arterial occlusions in young patients with Crohn's colitis and premature atherosclerosis: report of six cases. Am J Gastroenterol 1997; 92: 494-497 [PMID: 9068477]
26. Mutlu B, Ermeydan CM, Enç F, Fotbolcu H, Demirkol O, Bayrak F, Basaran Y. Acute myocardial infarction in a young woman with severe ulcerative colitis. Int J Cardiol 2002; 83: 183-185 [PMID: 12007694 DOI: 10.1016/S0167-5273(02)00043-8]
27. Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AA, Pounder RE. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989; 2: 1057-1062 [PMID: 2572794 DOI: 10.1016/S0140-6736(89)91078-7]
28. Sankey EA, Dhillon AP, Anthony A, Wakefield AJ, Sim R, More L, Hudson M, Sawyerr AM, Pounder RE. Early mucosal changes in Crohn's disease. Gut 1993; 34: 375-381 [PMID: 8472987 DOI: 10.1136/gut.34.3.375]
29. Dhillon AP, Anthony A, Sim R, Wakefield AJ, Sankey EA, Hudson M, Allison MC, Pounder RE. Mucosal capillary thrombi in rectal biopsies. Histopathology 1992; 21: 127-133 [PMID: 1505929 DOI: 10.1111/j.1365-2559.1992.tb00360.x]
30. Papa A, Danese S, Gasbarrini A, Gasbarrini G. Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1403-1409 [PMID: 11069310 DOI: 10.1046/j.1365-2036.2000.00860]
31. Bloom S, Kiilerich S, Lassen MR, Forbes A, Leiper K, Langholz E, Irvine EJ, O'Morain C, Lowson D, Orm S. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 871-878 [PMID: 15080848 DOI: 10.1111/j.1365-2036.2004.01926.x]
32. Thompson NP, Wakefield AJ, Pounder RE. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 1995; 108: 1011-1015 [PMID: 7698567 DOI: 10.1016/0016-5085(95)90197-3]
33. Tabibian JH, Streiff MB. Inflammatory bowel disease-associated thromboembolism: a systematic review of outcomes with anticoagulation versus catheter-directed thrombolysis. Inflamm Bowel Dis 2012; 18: 161-171 [PMID: 21805543 DOI: 10.1002/ibd.21307]
34. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol 2007; 102: 174-186 [PMID: 17100967 DOI: 10.1111/j.1572-0241.2006.00943.x]
35. Zitomersky NL, Verhave M, Trenor CC. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis 2011; 17: 458-470 [PMID: 20848518 DOI: 10.1002/ibd.21334]
36. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-430 [PMID: 16281932 DOI: 10.1111/j.1365-2141.2005.05753]
37. Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 1997; 90: 183-188 [PMID: 9093595 DOI: 10.1093/qjmed/90.3.183]
38. Landman C, Nahon S, Cosnes J, Bouhnik Y, Brixi-Benmansour H, Bouguen G, Colombel JF, Savoye G, Coffin B, Abitbol V, Filippi J, Laharie D, Moreau J, Veyrac M, Allez M, Marteau P. Portomesenteric vein thrombosis in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 582-589 [PMID: 23385240 DOI: 10.1097/ MIB.0b013e31827eea5f]
39. Undas A, Owczarek D, Gissel M, Salapa K, Mann KG, Butenas S. Activated factor XI and tissue factor in inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1447-1448 [PMID: 20049947 DOI: 10.1002/ibd.21206]
40. Cougard PA, Desjeux A, Vitton V, Baumstarck-Barrau K, Lesavre N, Grimaud JC. The usefulness of factor XIII levels in Crohn's disease. J Crohns Colitis 2012; 6: 660-664 [PMID: 22398040 DOI: 10.1016/j.crohns.2011.11.016]
41. Higaki S, Nakano K, Onaka S, Amano A, Tanioka Y, Harada K, Hashimoto S, Sakaida I, Okita K. Clinical significance of measuring blood coagulation factor XIIIA regularly and continuously in patients with Crohn's disease. J Gastroenterol Hepatol 2006; 21: 1407-1411 [PMID: 16911684 DOI: 10.1111/j.1440-1746.2006.04319.x]
42. Hayat M, Ariëns RA, Moayyedi P, Grant PJ, O'Mahony S. Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14: 249-256 [PMID: 11953689 DOI: 10.1097/00042737-200203000-00008]
43. Soendergaard C, Kvist PH, Seidelin JB, Nielsen OH. Tissueregenerating functions of coagulation factorXIII. J Thromb Haemost 2013; 11: 806-816 [PMID: 23406195 DOI: 10.1111/ jth.12169]
44. Van Bodegraven AA, Tuynman HA, Schoorl M, Kruishoop AM, Bartels PC. Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease. Scand J Gastroenterol 1995; 30: 580-585 [PMID: 7569767 DOI: 10.3109 /00365529509089793]
45. Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA. Plasma thrombinactivatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2008; 20: 912-916 [PMID: 18794606 DOI: 10.1097/MEG.0b013e3282faa759]
46. Owczarek D, Undas A, Foley JH, Nesheim ME, Jabłonski K, Mach T. Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD. J Crohns Colitis 2012; 6: 13-20 [PMID: 22261523 DOI: 10.1016/j.crohns.2011.06.005]
47. Owczarek D, Cibor D, Sałapa K, Cieśla A, Głowacki MK, Pocztar H, Mach TH. Anti-inflammatory and anticoagulant properties of the protein C system in inflammatory bowel disease. Pol Arch Med Wewn 2012; 122: 209-216 [PMID: 22538795]
48. Saibeni S, Vecchi M, Valsecchi C, Faioni EM, Razzari C, de Franchis R. Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies. Dig Dis Sci 2001; 46: 637-643 [PMID: 11318545]
49. Cromer WE, Mathis JM, Granger DN, Chaitanya GV, Alexander JS. Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol 2011; 17: 578-593 [PMID: 21350707 DOI: 10.3748/wjg.v17.i5.578]
50. Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2010; 16: 52-57 [PMID: 19575355 DOI: 10.1002/ ibd.20994]
51. Danese S, Sgambato A, Papa A, Scaldaferri F, Pola R, Sans M, Lovecchio M, Gasbarrini G, Cittadini A, Gasbarrini A. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol 2005; 100: 886-895 [PMID: 15784037 DOI: 10.1111/j.1572-0241.2005.41469.x]
52. Oussalah A, Guéant JL, Peyrin-Biroulet L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther 2011; 34: 1173-1184 [PMID: 21967576 DOI: 10.1111/j.1365-2036.2011.04864]
53. Collins CE, Rampton DS, Rogers J, Williams NS. Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997; 9: 1213-1217 [PMID: 9471028]
54. Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003; 52: 1435-1441 [PMID: 12970136 DOI: 10.1136/gut.52.10.1435]
55. Koutroubakis IE. Role of thrombotic vascular risk factors in inflammatory bowel disease. Dig Dis 2000; 18: 161-167 [PMID: 11279334 DOI: 10.1159/000051389]
56. Koutroubakis IE, Petinaki E, Anagnostopoulou E, Kritikos H, Mouzas IA, Kouroumalis EA, Manousos ON. Anti cardiolipin and anti-beta2-glycoprotein I antibodies in pa tients with inflammatory bowel disease. Dig Dis Sci 1998; 43: 2507-2512 [PMID: 9824143 DOI: 10.1023/A: 1026602803622]
57. Saibeni S, Ciscato C, Vecchi M, Boscolo Anzoletti M, Kaczmarek E, Caccia S, de Franchis R, Cugno M. Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis. J Thromb Haemost 2006; 4: 1510-1516 [PMID: 16839347 DOI: 10.1111/j.1538-7836.2006.01970.x]
58. Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Theodoropoulou A, Livadiotaki A, Paspatis G, Kouroumalis EA. Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case-control study. Inflamm Bowel Dis 2007; 13: 410-415 [PMID: 17206678 DOI: 10.1002/ ibd.20076]
59. Zhong M, Dong XW, Zheng Q, Tong JL, Ran ZH. Factor V Leiden and thrombosis in patients with inflammatory bowel disease (IBD): a meta-analysis. Thromb Res 2011; 128: 403-409 [PMID: 21831411 DOI: 10.1016/j.thromres.2011.07.014]
60. Papa A, Danese S, Grillo A, Gasbarrini G, Gasbarrini A. Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1247-1251 [PMID: 12818264 DOI: 10.1111/j.1572-0241.2003.07491.x]
61. Papa A, De Stefano V, Gasbarrini A, Chiusolo P, Cianci R, Casorelli I, Paciaroni K, Cammarota G, Leone G, Gas barrini G. Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. Blood Coagul Fibrinolysis 2000; 11: 499-503 [PMID: 10937811]
62. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3: 292-299 [PMID: 15670035 DOI: 10.1111/ j.1538-7836.2005.01141.x]
63. Van Hylckama Vlieg A, Komanasin N, Ariëns RA, Poort SR, Grant PJ, Bertina RM, Rosendaal FR. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 2002; 119: 169-175 [PMID: 12358922 DOI: 10.1046/ j.1365-2141.2002.03797]
64. Saibeni S, Vecchi M, Faioni EM, Franchi F, Rondonotti E, Borsi G, de Franchis R. Val34Leu factor XIII polymorphism in Italian patients with inflammatory bowel disease. Dig Liver Dis 2003; 35: 32-36 [PMID: 12725605 DOI: 10.1016/ S1590-8658(02)00008-7]
65. Magro F, Dinis-Ribeiro M, Araújo FM, Pereira P, Fraga MC, Cunha-Ribeiro LM, Tomé-Ribeiro A. High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003; 15: 1157-1163 [PMID: 14560147 DOI: 10.1097/00042737-2003 11000-00002]
66. Carty E, MacEy M, Rampton DS. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1169-1179 [PMID: 10971234 DOI: 10.1046/j.1365-2036.2000.00824.x]
67. Johannesdottir SA, Horváth-Puhó E, Dekkers OM, Cannegieter SC, Jørgensen JO, Ehrenstein V, Vandenbroucke JP, Pedersen L, Sørensen HT. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 2013; 173: 743-752 [PMID: 23546607 DOI: 10.1001/jamainternmed.2013.122]
68. Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 1831-1834 [PMID: 21784722 DOI: 10.1136/ard.2011.153536]
69. Masson PL. Thromboembolic events and anti-tumor necrosis factor therapies. Int Immunopharmacol 2012; 14: 444-445 [PMID: 22954485 DOI: 10.1016/j.intimp.2012.08.018]
70. Havrda DE, Rathbun S, Scheid D. A case report of warfarin resistance due to azathioprine and review of the literature. Pharmacotherapy 2001; 21: 355-357 [PMID: 11253860 DOI: 10.1592/phco.21.3.355.34208]
71. Shen J, Ran ZH, Tong JL, Xiao SD. Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther 2007; 26: 653-663 [PMID: 17697199 DOI: 10.1111/j.1365-2036.2007.03418.x]
72. Chande N, McDonald JW, Macdonald JK, Wang JJ. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010;: CD006774 [PMID: 20927749 DOI: 10.1002/14651858. CD006774.pub3]
73. Stadnicki A. Involvement of coagulation and hemostasis in inflammatory bowel diseases. Curr Vasc Pharmacol 2012; 10: 659-669 [PMID: 22272910 DOI: 10.2174/157016112801784495]
74. Chande N. Prevention of venous thromboembolism in hospitalized patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 669-671 [PMID: 23385239 DOI: 10.1097/ MIB.0b013e31827e7a0f]
75. Wang JY, Terdiman JP, Vittinghoff E, Minichiello T, Varma MG. Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events. World J Gastroenterol 2009; 15: 927-935 [PMID: 19248191 DOI: 10.3748/wjg.15.927]
76. Lazzerini M, Bramuzzo M, Maschio M, Martelossi S, Ventura A. Thromboembolism in pediatric inflammatory bowel disease: systematic review. Inflamm Bowel Dis 2011; 17: 2174-2183 [PMID: 21910180 DOI: 10.1002/ibd.21563]
77. Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO. Second European evidencebased consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013; 7: 1-33 [PMID: 23040453 DOI: 10.1016/j.crohns.2012.09.005]
78. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010; 4: 63-101 [PMID: 21122490 DOI: 10.1016/j.crohns.2009.09.009]